Cargando…
Synergy of R-(–)carvone and cyclohexenone-based carbasugar precursors with antibiotics to enhance antibiotic potency and inhibit biofilm formation
The widespread use of antibiotics in recent decades has been a major factor in the emergence of antibiotic resistances. Antibiotic-resistant pathogens pose increasing challenges to healthcare systems in both developing and developed countries. To counteract this, the development of new antibiotics o...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606123/ https://www.ncbi.nlm.nih.gov/pubmed/36289389 http://dx.doi.org/10.1038/s41598-022-22807-8 |
_version_ | 1784818230844456960 |
---|---|
author | Riester, Oliver Burkhardtsmaier, Pia Gurung, Yuna Laufer, Stefan Deigner, Hans-Peter Schmidt, Magnus S. |
author_facet | Riester, Oliver Burkhardtsmaier, Pia Gurung, Yuna Laufer, Stefan Deigner, Hans-Peter Schmidt, Magnus S. |
author_sort | Riester, Oliver |
collection | PubMed |
description | The widespread use of antibiotics in recent decades has been a major factor in the emergence of antibiotic resistances. Antibiotic-resistant pathogens pose increasing challenges to healthcare systems in both developing and developed countries. To counteract this, the development of new antibiotics or adjuvants to combat existing resistance to antibiotics is crucial. Glycomimetics, for example carbasugars, offer high potential as adjuvants, as they can inhibit metabolic pathways or biofilm formation due to their similarity to natural substrates. Here, we demonstrate the synthesis of carbasugar precursors (CSPs) and their application as biofilm inhibitors for E. coli and MRSA, as well as their synergistic effect in combination with antibiotics to circumvent biofilm-induced antibiotic resistances. This results in a biofilm reduction of up to 70% for the CSP rac-7 and a reduction in bacterial viability of MRSA by approximately 45% when combined with the otherwise ineffective antibiotic mixture of penicillin and streptomycin. |
format | Online Article Text |
id | pubmed-9606123 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-96061232022-10-28 Synergy of R-(–)carvone and cyclohexenone-based carbasugar precursors with antibiotics to enhance antibiotic potency and inhibit biofilm formation Riester, Oliver Burkhardtsmaier, Pia Gurung, Yuna Laufer, Stefan Deigner, Hans-Peter Schmidt, Magnus S. Sci Rep Article The widespread use of antibiotics in recent decades has been a major factor in the emergence of antibiotic resistances. Antibiotic-resistant pathogens pose increasing challenges to healthcare systems in both developing and developed countries. To counteract this, the development of new antibiotics or adjuvants to combat existing resistance to antibiotics is crucial. Glycomimetics, for example carbasugars, offer high potential as adjuvants, as they can inhibit metabolic pathways or biofilm formation due to their similarity to natural substrates. Here, we demonstrate the synthesis of carbasugar precursors (CSPs) and their application as biofilm inhibitors for E. coli and MRSA, as well as their synergistic effect in combination with antibiotics to circumvent biofilm-induced antibiotic resistances. This results in a biofilm reduction of up to 70% for the CSP rac-7 and a reduction in bacterial viability of MRSA by approximately 45% when combined with the otherwise ineffective antibiotic mixture of penicillin and streptomycin. Nature Publishing Group UK 2022-10-26 /pmc/articles/PMC9606123/ /pubmed/36289389 http://dx.doi.org/10.1038/s41598-022-22807-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Riester, Oliver Burkhardtsmaier, Pia Gurung, Yuna Laufer, Stefan Deigner, Hans-Peter Schmidt, Magnus S. Synergy of R-(–)carvone and cyclohexenone-based carbasugar precursors with antibiotics to enhance antibiotic potency and inhibit biofilm formation |
title | Synergy of R-(–)carvone and cyclohexenone-based carbasugar precursors with antibiotics to enhance antibiotic potency and inhibit biofilm formation |
title_full | Synergy of R-(–)carvone and cyclohexenone-based carbasugar precursors with antibiotics to enhance antibiotic potency and inhibit biofilm formation |
title_fullStr | Synergy of R-(–)carvone and cyclohexenone-based carbasugar precursors with antibiotics to enhance antibiotic potency and inhibit biofilm formation |
title_full_unstemmed | Synergy of R-(–)carvone and cyclohexenone-based carbasugar precursors with antibiotics to enhance antibiotic potency and inhibit biofilm formation |
title_short | Synergy of R-(–)carvone and cyclohexenone-based carbasugar precursors with antibiotics to enhance antibiotic potency and inhibit biofilm formation |
title_sort | synergy of r-(–)carvone and cyclohexenone-based carbasugar precursors with antibiotics to enhance antibiotic potency and inhibit biofilm formation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606123/ https://www.ncbi.nlm.nih.gov/pubmed/36289389 http://dx.doi.org/10.1038/s41598-022-22807-8 |
work_keys_str_mv | AT riesteroliver synergyofrcarvoneandcyclohexenonebasedcarbasugarprecursorswithantibioticstoenhanceantibioticpotencyandinhibitbiofilmformation AT burkhardtsmaierpia synergyofrcarvoneandcyclohexenonebasedcarbasugarprecursorswithantibioticstoenhanceantibioticpotencyandinhibitbiofilmformation AT gurungyuna synergyofrcarvoneandcyclohexenonebasedcarbasugarprecursorswithantibioticstoenhanceantibioticpotencyandinhibitbiofilmformation AT lauferstefan synergyofrcarvoneandcyclohexenonebasedcarbasugarprecursorswithantibioticstoenhanceantibioticpotencyandinhibitbiofilmformation AT deignerhanspeter synergyofrcarvoneandcyclohexenonebasedcarbasugarprecursorswithantibioticstoenhanceantibioticpotencyandinhibitbiofilmformation AT schmidtmagnuss synergyofrcarvoneandcyclohexenonebasedcarbasugarprecursorswithantibioticstoenhanceantibioticpotencyandinhibitbiofilmformation |